A retrospective study of the addition of ciprofloxacin to clarithromycin and ethambutol in the treatment of disseminated Mycobacterium avium complex infection

International Journal of STD and AIDS

Volumn 10, Issue 12, 1999, Pages 791-794

  Keiser, Philip ^a,b,c   Nassar, Naiel ^a,b   Skiest, Daniel ^a   Rademacher, Steven ^a,b   Smith, James W ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b VA NORTH TEXAS HEALTH CARE SYSTEM   (United States)

^c UNIVERSITY OF TEXAS AT DALLAS   (United States)

Author keywords

Disseminated Mycobacterium avium complex; Multi drug antibiotic therapy

Indexed keywords

CIPROFLOXACIN; CLARITHROMYCIN; ETHAMBUTOL;

ARTICLE; DRUG EFFICACY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MYCOBACTERIOSIS; MYCOBACTERIUM INTRACELLULARE AVIUM; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SURVIVAL TIME;

ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; ANTITUBERCULAR AGENTS; CD4 LYMPHOCYTE COUNT; CIPROFLOXACIN; CLARITHROMYCIN; COHORT STUDIES; DRUG THERAPY, COMBINATION; ETHAMBUTOL; HIV INFECTIONS; HUMANS; LONGITUDINAL STUDIES; MALE; MYCOBACTERIUM AVIUM-INTRACELLULARE INFECTION; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 0032746563     PISSN: 09564624     EISSN: None     Source Type: Journal    
DOI: 10.1258/0956462991913565     Document Type: Article

References (26)

1. 1 Nightingale SD, Byrd LT, Southern PM, Jockusch JA, Cal SX, Wymme BA. Incidence of Mycobacterium avium-intracellulare complex bacteremia in HIV positive patients. J Infect Dis 1992;165:1082-5
2. 2 Havlik JA Jr, Horsburgh CR Jr, Metchock B, Williams PP, Fann SA, Thompson SE III. Disseminated Mycobacterium avium complex infection: clinical identification and epidemiologic trends. J Infect Dis 1992;165:577-80
3. 3 Jacobson MA, Hopewell PC, Yajkio DM, et al. Natural history of disseminated Mycobacterium avium complex in AIDS. J Infect Dis 1991;164:994-8
4. 4 Horsburgh CR Jr, Havlik JA, Ellis DA, et al. Survival of patients with acquired immunodeficiency syndrome and disseminated Mycobacterium avium complex infection with and without anti-mycobacterial chemotherapy. Am Rev Respir Dis 1991;144:557-9
5. 5 Chaisson RE, Benson CA, Dube MP, et al. Clarithromycin therapy for bacteremic Mycobacterium avium complex diseases. A randomized, double-blind, dose-ranging study in patients with AIDS. AIDS Clinical Trials Group Protocol 157 Study Team. Ann Intern Med 1994;121:905-11
6. 6 Doucet-Populaire F, Truffot-Pernot C, Grosset J, Jarlier V. Acquired resistance in Mycobacterium avium complex strains isolated from AIDS patients and beige mice during treatment with clarithromycin. J Antimicrob Chemother 1995;36:129-36
7. 7 Cohn D. Relapse of disseminated Mycobacterium avium complex disease and emergence of resistance to clarithromycin despite treatment with a multidrug regimen. 3rd Conference on Retrovirology and Opportunistic Infections, 28 January-1 February 1996
8. 8 Shafran SD, Singer J, Zarowny DP, et al. A comparison of two regimens for the treatment of Mycobacterium avium complex bacteremia in AIDS: rifabutin, ethambutol, and clarithromycin versus rifampin, ethambutol, clofazimine, and ciprofloxacin. N Engl J Med 1996;335:377-83
9. 9 Horsburgh CR Jr. Advances in the prevention and treatment of Mycobacterium avium disease. N Engl J Med 1996;335:428-30
10. 10 Piersimoni C, Tortoli E, Mascellino MT, et al. Activity of seven antimicrobial agents, alone and in combination, against AIDS-associated isolates of Mycobacterium avium complex. J Antimicrob Chemother 1995;36:497-502
11. 11 Shiratsuchi H, Jacobs MR, Pearson AJ, Venkataprasad N, Klopman G, Ellner JJ. Comparison of the activity of fluoroquinolones against Mycobacterium avium in cell-free systems and a human monocyte in-vitro infection model. J Antimicrob Chemother 1996;37:491-500
12. 12 Yajko DM, Sanders CA, Madej JJ, Cawthon VL, Hadley WK. In vitro activities of rifabutin, azithromycin, ciprofloxacin, clarithromycin, clofazimine, ethambutol, and amikacin in combinations of two, three, and four drugs against Mycobacterium avium. Antimicrob Agents Chemother 1996;40:743-9
13. 13 Rastogi N, Bauriaud RM, Bourgoin A, et al. French multicenter study involving eight test sites for radiometric determination of activities of 10 antimicrobial agents against Mycobacterium avium complex. Antimicrob Agents Chemother 1995;39:638-44
14. 14 Young LS, Wu M, Brender J, for the Spirofloxacin Study Group. Pilot Study of Sparfloxacin for M. avium bacteremia complicating AIDS (Abstract No. 897). 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy, Anaheim, CA, 1992
15. 15 Dautzenberg R, Katlama C, Chastamg C, et al. Sparfloxacin versus placebo in AIDS patients with disseminated M. avium disease (Abstract No. 918). Am J Resp Dis 1993
16. 16 Alangaden GJ, Lerner SA. The clinical use of fluoroquinolones for the treatment of mycobacterial disease. Clin Infect Dis 1997;25:1213-21
17. 17 Jacobson MA, Yajko D, Northfelt D, et al. Randomized placebo controlled trial of rifampim, ethambutol, and ciprofloxacin for AIDS patients with disseminated Mycobacterium avium complex infection. J Infect Dis 1993;168:112-19
18. 18 Chiu J, Nussbaum J, Bozette S, et al. Treatment of disseminated Mycobacterium avium complex infection in AIDS with amikacin, ethambutol, rifampim and ciprofloxacin. Ann Intern Med 1990;113:258-61
19. 19 Benson CA, Kessler HA, Pottage JC Jr, Trenholme GM. Successful treatment of acquired immunodeficiency syndrome related therapy of Mycobacterium avium complex disease with a multiple drug regimen including amikacin. Arch Intern Med 1991;151:582-5
20. 20 DeLalla F, Maserati R, Scarpellini P, et al. Clarithromycin-ciprofloxacin-amikacin therapy for Mycobacterium avium-Mycobacterium intracellulare bacteremia in patients with AIDS. Antimicrob Agents Chemother 1992;361:567-9
21. 21 Kemper CA, Meng T-C, Nussbaum J, et al. Treatment of Mycobacterium avium complex bacteremia in AIDS with a four drug oral regimen: rifampin, ethambutol, clofazimine, and ciprofloxacin. Ann Intern Med 1992;116:466-72
22. 22 Kaplan JE, Masur H, Holmes KK. USPHS/IDSA Guidelines for the Prevention of Opportunistic Infections in Persons Infected with Human Immunodeficiency Virus. 1997;46(RR-12)
23. 23 Friedman LA, Hidalgo J, Bartnyska LM, et al. The severity classification system for acquired immunodeficiency syndrome hospitalizations. Association with survival after discharge and inpatient resource use. Med Care 1996;34:178-84
24. 24 Deeks SG, Smith M, Holodniy M, Kahn JO. HIV-1 protease inhibitors. A review for clinicians. JAMA 1997;277:145-53
25. 25 Carpenter CC, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel. International AIDS Society - USA. JAMA 1996;276:146-54
26. 26 Fauci AS, Bartlett JG, Goosby EP, Smith MD, for Department of Health and Human Services (DHHS) and the Henry J. Kaiser Family Foundation. Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents. MMWR 1999;18(RR-48)